Objectives: Human leukocyte antigen alloimmunization is caused by exposure to HLA antigens through transfusion, pregnancy, or transplant. Our study objective was to present the rate of positivity of anti-HLA antibody considering the effects of a single sensitization event in kidney transplant candidates at our center. Materials and Methods: Our study reviewed 606 kidney transplant candidates. Patient sera were analyzed using Luminex xMAP technology. Panel reactive antibody positivity rates and antibody strengths in patients were analyzed according to a single sensitization event. Results: Our findings showed 246 patients (40.6%) with a panel reactive antibody > 0, of which 97 (39.4%) were sensitized from a single event, 119 (48.4%) were sensitized by multiple events, and 30 (12.2%) had no known sensitizing event. Considering patients sensitized by a single event with a panel reactive antibody > 0, we found that 25.8% had received transplant only, 49.5% had previous pregnancy only, and 24.7% had received transfusion only. The strength of antibodies was significantly higher in patients with previous transplant procedures than in those with transfusion for HLA-A (P < .01), HLA-B (P < .05), HLA-C (P < .05), HLA-DR (P < .001), HLA-DQ (P < .05), and HLA-DP (P < .05). Similarly, we observed significantly higher median fluorescence intensity values for HLA-A, -DR, -DQ, and -DP loci in patients with a previous transplant procedure versus preg nancy. The strength of antibodies against HLA-DR was significantly higher in patients with a previous pregnancy compared with those with transfusion (P < .01). Conclusions: This study documents the profile of HLA alloimmunization in kidney transplant candidates. In particular, transplant procedures appear to have a greater immunologic impact, followed by pregnancy and transfusion. Our data confirm and are in accordance with those of several studies in which the sensitization events were associated with higher prevalence of anti-HLA antibodies.
Introduction
The success of a transplant depends on the degree of human leukocyte antigen (HLA) compatibility between donor and recipient. 1 Alloimmunization is the activation of the adaptive immune system to foreign HLA resulting in the generation of antibodies. 2 It occurs after exposure to non-self tissue through blood transfusion, pregnancy, and previous transplants; therefore, the determination of anti-HLA class I and II antibodies plays a crucial role for the initial work-up of patients on a wait list for kidney transplant. The detection and identification of anti-HLA antibodies by the Luminex method have led to increased sensitivity and specificity compared with conventional cytotoxicity assays, allowing improved management of patients on wait lists for organ transplant. 3 In end-stage renal disease (ESRD) patients, the value of panel reactive antibody (PRA), commonly accepted as a routine practice in transplant centers, represents an estimate of alloimmunization. In addition, the probability of receiving a kidney transplant is inversely related to the PRA percentage. 4, 5 Several studies have evaluated whether alloimmunization after previous transfusion, pregnancy, and transplant is associated with a significantly higher prevalence of anti-HLA antibodies. 6, 7 In the 1980s, many transplant centers performed blood transfusions before kidney transplant to improve allograft survival. 8 Subsequently, this shared protocol was discarded because of the high risk of anti-HLA antibody sensitization and infection. 9 A recent metaanalysis reported that higher rates of anti-HLA antibodies were found in patients with a previous transfusion compared with those without. 10 In pregnancy-sensitized patients, anti-HLA antibodies directed to paternal HLA mismatches were found in 15% to 30% of women, 11 and the immunogenicity of mismatches may be due to the HLA phenotype of the wife and of the husband. 12 Solid-organ transplant is a significant immunizing event. Indeed, a considerable amount of ESRD patients were immunized by previous transplant procedures, 13 usually owing to reduction of immunosuppression after nephrectomy or triggering of proinflammatory events. 9,14 "Natural" anti-HLA antibodies were found in non-alloimmunized healthy males. 15 It has been suggested that anti-HLA antibodies in patients without a history of known sensitization events were developed in response to cross-reactive epitopes on microorganisms, allergens, and ingested proteins. 9, 15, 16 The aim of our study was to present the rate of positivity of anti-HLA antibody considering the effect of a single sensitizing event in kidney transplant candidates in the Campania Region (Southern Italy).
Materials and Methods

Patients
We analyzed 606 ESRD patients (mean age of 51.8 ± 11.5 y), of which 370 were male patients (61%) and 236 were female patients (39%) on a wait list for deceased-donor kidney transplant from March 2014 to December 2015 (Table 1) . Our population included patients with and without sensitization events. The data on potential risk factors causing the development of anti-HLA antibodies (transfusion, pregnancy, and previous transplant) were obtained at the time of patient enrollment and updated for the duration of maintenance on wait lists. The effects of each sensitizing event on HLA alloimmunization were analyzed, considering patients exposed to a single sensitizing event. Written informed consent was obtained from each patient recruited in this study, and the study was performed as per the Declaration of Helsinki.
Anti-HlA antibody detection
All samples were studied for the presence of anti-HLA class I and II antibodies of immunoglobulin G type by the Luminex xMAP technology using screening test kits (LABScreen Mixed LSM12; One Lambda, Canoga Park, CA, USA). The value of PRA was determined by identification test kits (LABScreen PRA: LS1PRA and LS2PRA; One Lambda). To characterize the antibody specificity, sera were tested with coated beads recombinant for HLA class I and II single antigens (LS1A04 for class I and LS2A01 for class II; One Lambda). Tests were made according to the manufacturer's instructions as previously reported. 17 In brief, 5 μL of beads coated with HLA antigens were incubated with 20 μL of serum samples for 30 minutes, and the remainder was washed off. This was followed by a subsequent incubation of 30 minutes with anti-human immunoglobulin G antibody conjugated to R-phycoerythrin and washings. The fluorescent emission of phycoerythrin from each bead was detected using the LABScan flow analyzer (Luminex 100/200) and analyzed with HLA Fusion version 3.0 software (One Lambda). Patients with PRA > 0% were considered positive. Median fluorescence intensity (MFI) values of patient sera were normalized with the appropriate negative control. Values greater than 1000 were accepted as positive. PRA-positive patients and relative antibody strengths were analyzed according to the different sensitization events.
Statistical analyses
Baseline demographic characteristics for each group were summarized using descriptive statistics. A comparison between groups was performed using Fisher exact test and chi-square test for categorical variables and t test for continuous variables. P values < .05 were considered statistically significant.
Results
In this study, 606 patients on wait lists for kidney transplants were analyzed for the presence of anti-HLA class I and II antibodies. Of these, 246 patients (40.6%) were found with PRA > 0, with 97 patients sensitized from a single event, 119 patients sensitized by multiple events, and 30 patients with no known sensitizing event (control group). In the 97 patients sensitized by a single event with a PRA > 0, we found that 25.8% were sensitized by transplant only, 49.5% by previous pregnancy only, and 24.7% by transfusion only (Table 2) . Table 3 shows the prevalence of anti-HLA class I and II antibodies in ESRD patients with single sensitizing events. Anti-HLA class I positive rates were significantly higher in patients with previous transplant (23.7%; P < .001), pregnancy (42.2%; P < .01), or transfusion (20.6%; P < .001) compared with patients without any identifiable sensitizing event (9.1%). The same results were seen for class II, with rates of 24.7% of patients sensitized by previous transplant (P < .001), 31.9% of patients sensitized by pregnancy (P < .001), and 17.5% of patients sensitized by previous transfusion (P < .001) compared with patients without any identifiable sensitizing event (3.0%) ( Table 3) .
As shown in Table 4 , a significant prevalence of anti-HLA antibodies versus HLA-A (P < .05) and HLA-DR (P < .001) loci in patients with previous transplant compared with those with pregnancy was observed. Likewise, the prevalence of anti-HLA antibodies versus HLA class II loci was significantly higher in patients with previous transplant than in those with transfusion ( (Table 5) . Similarly, a significantly higher prevalence of anti-HLA antibodies only for HLA-A, -DR, -DQ, and -DP loci in patients who had a previous transplant compared with those who had a previous pregnancy was observed. In addition, MFI values for HLA-B and HLA-DQ antibodies were found to be significantly different in patients with previous pregnancy compared with those with transfusions (for all, P < .05); in particular, the antibody strength against the HLA-DR locus was significantly higher in sera of patients with a previous pregnancy than in those with transfusion (9157 vs 1861; P < .01) ( Table 5) .
Discussion
Allosensitization constitutes a major obstacle to the success of transplant in ESRD patients, prolonging wait times and reducing renal graft survival. The effects of transfusion, pregnancy, and transplant on HLA alloimmunization were compared in this study. Several studies have reported high rates of leukocyte alloimmunization in renal transplant candidates. 18, 19 Similarly to that reported by Hyun et al, 6 we found that the percentage of sensitized ESRD patients was 40.6%. As expected, sensitizing events were associated with higher prevalence of anti-HLA antibodies compared with patients without sensitizing events. The US Renal Data System 2012 annual report confirmed the sensitization effect of transfusion. 20 Similarly to that shown by Hyun and associates, 6 24.7% of our transplant candidates with a history of blood transfusion developed anti-HLA antibodies. Antibody development against HLA antigens after transfusion is affected by the number and type of transfusions. Indeed, the transfusion of filtered versus unfiltered blood components plays a role in the rate of alloimmunization to HLA antigens; unfortunately, however, there was no information for our study about the type of blood components and the number of transfusion in patients.
The effects of pregnancy on the incidence of anti-HLA immunization were explored in a group of patients. In agreement with other investigators, 12, 21 49.5% of patients on kidney transplant wait lists who were pregnant developed anti-HLA antibodies. In particular, anti-HLA antibodies directed to class I were more frequent than class II, although both were produced, as also described by Hickey and colleagues. 2 The generation and maintenance of serum alloantibodies in pregnancy are due to the continuous presence of fetopaternal cells in the mother and may depend on the production rate of plasma cells and on antibody half-life once in the circulation. 14 As shown in several studies that investigated sera of sensitized patients by pregnancy, 66% of these patients showed microchimerism. 22, 23 However, a single sensitizing event as pregnancy was not a potential risk factor for the development of anti-HLA antibodies; in fact, despite sensitizing events, not all women become sensitized after exposure to fetal alloantigens. This phenomenon could be explained by the non-self-self paradigm of HLA epitope immunogenicity. It is possible that the epitope on the immunizing HLA antigen is structurally similar to the corresponding self epitope of the antibody producer. 24, 25 In particular, every individual has a repertoire of B cells with low avidity for epitopes of receptors expressed on own cells that does not lead to the activation of B cells and antibody production, although exposure to non-self epitopes can induce an antibody response. 26 Thus, an auto reactive component is also required for alloantibody responses to an HLA mismatch. 27 In the present study, in accordance with Lopes and associates, 7 we confirmed that a transplant has a high immunizing effect for both HLA class I and II compared with pregnancy and transfusion. Likewise, when we compared the antibody strengths (MFI values), as also reported by several authors, 6, 28, 29 we confirmed that a transplant, mainly for HLA class II, has a significantly higher antibody strength than pregnancy or transfusion. The presence of anti-HLA antibodies in our patients without any known sensitization event (11.4%) and the clinical significance of such antibodies are not clear. On the other hand, the high rate of alloimmunization can be explained by reactivity antibody against pathogens, allergens, or cross-reactive epitopes that may be able to bind to HLA-coated beads. This hypothesis is supported by previous studies. 16, 30 Moreover, considering the evidence that hepatitis B vaccine may cause HLA alloimmunization, 31 a further explanation for this unexpected positivity may be the cross-sensitization following vaccination, which is recommended in ESRD patients. However, it also was postulated that the process of attaching HLA molecules to the beads causes denaturation of these molecules with the expression of epitopes that would not be present naturally on the cell surface. 30 
Conclusions
In kidney transplant, the presence of HLA antibodies is responsible for its rejection and it is predictive of graft loss. Therefore, an understanding of the HLA alloimmunization is of considerable importance. This study documented the immunologic profile of ESRD patients who were on wait lists for an organ transplant in the Campania Region. Our results are in line with those reported in several studies in which the effects of transplant appear to have the highest immunization impact for class I and II HLA antigens, followed by pregnancy and transfusion.
